AI-generated summary
The authors pooled eight studies of transcranial photobiomodulation for depressive symptoms and report a large overall effect with significant heterogeneity. Among the few double-blind, sham-controlled studies in major depressive disorder, the advantage over sham was not statistically significant, and the authors describe the overall support as weak and call for larger randomized trials.
- Studies included
- 8
- Who or what was studied
- People with depressive symptoms regardless of diagnosis, with a subgroup analysis of participants with major depressive disorder
- Limits stated in the abstract
- The authors note significant heterogeneity, only three sham-controlled studies in major depressive disorder, and a likely sample size bias.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Meta-analysis, Photobiomodulation, Sham, Heterogeneity, Confidence interval, Sample size, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.